 In addition to his academic research, Professor Suslick has had significant entrepreneurial experience.He was the lead consultant for Molecular Biosystems Inc. and part of the team that commercialized the first echo contrast agent for medical sonography, Albunex™, which became Optison™ by GE Healthcare.In addition, he was the founding consultant for VivoRx Pharmaceuticals and helped invent and commercialize Abraxane™, albumin microspheres with a paclitaxel core, which is the predominant current delivery system for taxol chemotherapy for breast cancer; VivoRx became Abraxis Bioscience, which was acquired by Celgene for $2.9 billion.